HOME >> BIOLOGY >> NEWS
AVELOX as effective as multi-dose combination therapy for intra-abdominal infections

Schering-Plough Corporation (NYSE: SGP) today reported that monotherapy with the once-daily, broad-spectrum antibiotic AVELOX (moxifloxacin HCl) was as effective and well tolerated as a standard multi-dose combination antibiotic regimen in the treatment of patients with complicated intra-abdominal infections (cIAI), according to results of a study involving 681 patients published in the current issue of the Annals of Surgery.(1) AVELOX, the only marketed fluoroquinolone antibiotic approved by the U.S. Food and Drug Administration (FDA) as monotherapy to treat cIAI, was shown to be effective at eradicating the most common bacteria that cause cIAI, including E. coli and B. fragilis.

In the study, patients who took 400 mg once daily of AVELOX intravenous (I.V.) followed by oral monotherapy achieved similar clinical cure rates (80 percent) at the test-of-cure visit (the primary efficacy endpoint) as patients who took a standard regimen of I.V. piperacillin-tazobactam followed by oral amoxicillin-clavulanate (78 percent).

Importantly, AVELOX demonstrated a significantly higher cure rate of 82 percent compared to 55 percent for the combination therapy among patients who acquired their cIAI in a hospital setting (including both mild-to-moderate and more severe hospital-acquired infections). Hospital-acquired infections are often caused by more resistant bacteria than community-acquired infections. Clinical cure rates for patients with community-acquired infections were similar between the two treatment groups.

The incidence of adverse events in the study due to any cause was similar for the two treatment groups, with the majority being mild or moderate in nature. The most common adverse events were nausea, hypokalemia, abdominal pain and constipation. The incidence of drug-related serious adverse events or premature discontinuation due to adverse events was similar for the two treatment groups.

"The results of this study are
'"/>


25-Jul-2006


Page: 1 2 3

Related biology news :

1. FDA approves AVELOX (moxifloxacin HCl) for treatment of complicated intra-abdominal infections
2. Smokeless tobacco more effective than cigarettes for delivering dangerous carcinogens into the body
3. Developing a more effective vaccine for tuberculosis
4. Cost-effective method for gene silencing is featured in Cold Spring Harbor Protocols
5. Implanon, Norplant and Jadelle are all effective contraceptives -- but side effects vary
6. High blood pressure medication strategy proves effective in Hispanic women
7. New compound effectively treats fungal infections
8. Northern forests less effective than tropical forests in reducing global warming
9. Cisplatin is more effective than carboplatin for treating nonsmall cell lung cancer
10. Scientists develop new drugs to fight colon and breast cancer more effectively
11. Avian influenza survivors antibodies effective at neutralising H5N1 strain

Post Your Comments:
(Date:4/18/2014)... Asteroid and comet impacts can cause widespread ecological ... even global scales. But new research from Brown University ... ancient life at the time of an impact. , ... has found fragments of leaves and preserved organic compounds ... in Argentina. The material could provide a snapshot of ...
(Date:4/17/2014)... A drug under clinical trials to treat tuberculosis ... drugs that act against various bacteria, fungal infections and ... University of Illinois chemists and collaborators. , Led by ... determined the different ways the drug SQ109 attacks the ... target other pathogens from yeast to malaria and ...
(Date:4/17/2014)... of stem cell therapies to cure a variety of ... populations based on cell surface markers. Researchers from the ... is highly expressed in a type of stem cells ... in an article in BioResearch Open Access , ... The article is available free on the ...
Breaking Biology News(10 mins):Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Multitarget TB drug could treat other diseases, evade resistance 2
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
Cached News: